Please login to the form below

Not currently logged in
Email:
Password:

Shire appoints Soren Tulstrup to lead its MPS franchise

He joins with experience from Santaris Pharma, Merck & Co, Sandoz and Abbott

Soren Tulstrup has joined Shire's Human Genetic Therapies business as franchise lead, MPS (mucopolysaccharides).

He will be responsible for developing global strategy for the MPS franchise, where Shire's current lead product is Elaprase (idursulfase) for Hunter syndrome.

Tulstrup will also play a key role in strategic decisions made about the company's rare disease portfolio, which includes 2010 Prix Galien winner Firazyr (icatibant) and Fabry disease drug Replagal (agalsidase alfa).

In his new role, Tulstrup will report to Sylvie Grégoire, president of Shire HGT, and be based in Shire's office in Nyon, Switzerland.

“Shire HGT is well positioned for continued sustained growth, with a strong portfolio of therapies for patients suffering from rare genetic diseases and a pipeline with significant potential,” said Sylvie Grégoire, president, Shire HGT.

“We believe Soren's extensive global experience will be invaluable in maximising the full potential of the MPS franchise as we provide therapies to patients with rare conditions that enable them to lead better lives,”.

Currently vice chairman of trade association EBE (European Biopharmaceutical Enterprises), Tulstrup was formerly president and CEO of Santaris Pharma, where he led business development efforts resulting in four major partnership agreements, including an ongoing collaboration with Shire.

Prior to this he spent over a decade at Merck & Co, both in Europe and the US, and has also held sales and marketing positions at Sandoz and Abbott Laboratories.

31st July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics